Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor

Leukemia and Lymphoma

Volumn 45, Issue 11, 2004, Pages 2353-2354

  Bompas, Emmanuelle ^a   Velay, Brigitte ^b   Byal, Jean Yves ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Clinique Saint Jean   (France)

Author keywords

Gastrointestinal stromal tumor; Imatinib; MALT lymphoma; Rituximab

Indexed keywords

CD20 ANTIGEN; CD79A ANTIGEN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMATINIB; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BONE MARROW TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROSCOPY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; LYMPH NODE METASTASIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; TUMOR LOCALIZATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LYMPHOMA; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MIDDLE AGED; PIPERAZINES; PREDNISOLONE; PYRIMIDINES; RECURRENCE; VINCRISTINE;

EID: 8644268102     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190412331272712     Document Type: Article

References (8)

1. Miettinen, M., Monihan, J.M., Sarlomo-Rikala, M., Kovatich, A.J., Carr, N.J., Emory, T.S., et al. (1999) " Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases", Am. J. Surg. Pathol., 23(9), 1109-1118.
2. Heinrich, M.C., Blanke, C.D., Druker, B.J. and Corless, C.L. (2002) "Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies", J. Clin. Oncol., 20(6), 1692-1703.
3. Thieblemont, C., Berger, F., Dumontet, C., Moullet, I., Bouafia, F., Felman, P., et al. (2000) "Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed", Blood, 95(3), 802-806. Review.
4. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., et al. (1994) "A revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group", Blood, 84(5 ), 1361-1302.
5. van Oosterom, A.T., Judson, L, Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., et al. (2001) " European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study", Lancet, 358 9291), 1421-1423.
6. Visconti, J.L., Petruska, P.J., Dunphy, C.H., Presti, M.E., Giacaman, M.H., Dunphy, F.R., et al. (1999) "Rituximab in the treatment of gastrointestinal mucosa associated lymphoid tissue (MALT) lymphoma", Blood, 94(10), Pt. 2 Suppl.1, 270b.
7. Conconi, A., Martinelli, G., Thieblemont, C., Ferreri, A.J., Devizzi, L., Peccatori, F., et al. (2003) "Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type", Blood, Jul 3 [Epub ahead of print].
8. Colucci, F. and Di Santo, J.P. (2000) "The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells", Blood, 95(3), 984-991.